Oppenheimer Initiates Prothena With Outperform

Analysts at Oppenheimer initiated coverage on shares of Prothena PRTA with a Outperform rating. The target price for Prothena is set to $40. Prothena shares have dropped 1.50% over the past 52 weeks, while the S&P 500 index has surged 16.93% in the same period. Prothena's shares fell 0.71% to close at $20.94 yesterday.